Oxford Nanopore and UK to develop pathogen surveillance system
Oxford Nanopore has entered a strategic partnership with the UK Government to create a pathogen surveillance system in the National…
Infectious Disease
-
-
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through
Matinas BioPharma has halted all product development activities and fired 80% of its staff, including three members of senior management,…
-
Spero’s stock slides after antibiotic flops in Phase II trial
Spero Therapeutics has suspended the development of its antibiotic SPR720, after the therapy failed to meet the primary endpoint in a Phase…
-
Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children two to 11…
-
US CDC AdCom recommends lowering the age for pneumococcal vaccines
A US Centers for Disease Control and Prevention’s (CDC) Advisory Committee (AdCom) on Immunization Practice (ACIP) voted in favour of…
-
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo to…
-
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
MSD (Merck & Co) is planning to get its respiratory syncytial virus (RSV) vaccine, clesrovimab, approved and launched before the…
-
ProductLife boosts drug development with IntiQuan acquisition
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics. The move enhances PLG's capabilities…
-
Resilience secures funds to enhance production of essential medicine components
National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing. Resilience received…
-
Gilead signs agreements to facilitate access to HIV prevention drug
Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to facilitate access to lenacapavir,…
